Fig. 7

Effects of Nano-DOX and DOX on MDSCs infiltration in tissues and G-CSF expression. a Immunofluorescent staining of MDSCs markers CD11b and Gr-1 in 4T1 tumor xenografts at the end of 3-week treatment of Nano-DOX or DOX. b Immunofluorescent staining of MDSCs markers CD11b and Gr-1 in spleen and H&E staining of granulocytes in liver and lungs. c RT-PCR analysis of G-CSF mRNA levels in in vitro 4T1 cells treated with Nano-DOX or DOX. d ELISA analysis of G-CSF secretion from in vitro 4T1 cells treated with Nano-DOX or DOX. e Immunohistochemical staining of G-CSF in 4T1 tumor xenografts at the end of 3-week treatment of Nano-DOX or DOX. f Serum levels of G-CSF in 4T1 tumor-bearing mice at the end of 3-week treatment of Nano-DOX or DOX, assayed by ELISA. (Duration of Nano-DOX or DOX treatment was 24 h for the in vitro cell experiments.) Values were mean ± SD (n = 3 for in vitro experiments and n = 5 for in vivo experiments, *p < 0.05, **p < 0.01)